Capital Increase / Dilution2026-08-19

Listing Date Delayed for Paid-in Capital Increase

UNI

한국유니온제약

080720

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2767

Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • Previous Listing Date: August 28, 2026
  • • New Listing Date: September 4, 2026
  • • Original Submission Date: May 18, 2026
  • • Court Approval Date for Reorganization Plan: May 12, 2026

AI Analysis Summary

UNION KOREA PHARM CO.,Ltd announced an amendment to its Material Fact Report regarding a paid-in capital increase. The primary change is a delay in the new share listing date from August 28, 2026, to September 4, 2026, due to administrative procedures with the Korea Securities Depository. This capital increase is part of a reorganization plan approved by the Seoul Rehabilitation Court on May 12, 2026, which also includes debt-to-equity conversion and capital reduction. The third-party allocation capital increase is expected to result in a change of the largest shareholder. The amendment itself has a neutral financial impact, as it only adjusts the listing schedule for a previously announced capital increase.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.